At the Consumer Electronics Show in Las Vegas, Insulet showcased its Omnipod® platform under the banner of “liveable technology,” presenting an immersive booth experience that featured hands-on demonstrations of its tubeless insulin pumps. The company highlighted its Omnipod 5 Automated Insulin Delivery System, which integrates a proprietary algorithm with third-party continuous glucose monitoring via Bluetooth to adjust insulin delivery every five minutes. During expert panel sessions, Insulet executives disclosed that more than 120,000 users worldwide now rely on Omnipod systems, representing year-over-year user growth of 28%. Media demonstrations emphasized the Pod’s 72-hour wear time and automated basal rate adjustments, positioning the system as a leader in reducing daily management burdens for people with insulin-dependent diabetes.

In remarks at CES, Insulet announced that international sales accounted for 35% of total revenue in the prior fiscal year, with distribution expanded into six new markets across Asia and South America. The company reported a 42% increase in non-U.S. shipments over the last 12 months, driven by strategic partnerships with independent distributors and direct pharmacy channels. Insulet’s global installed base surpassed 150,000 Pods in service as of January 2026, up from 117,000 one year earlier. Management reiterated guidance for annual revenue growth of 25% to 30% and confirmed plans to invest $75 million in manufacturing capacity to support projected demand through 2028.

Beyond its existing commercial offerings, Insulet detailed progress on two clinical programs: a next-generation Omnipod with integrated dual-hormone delivery and a slim-profile Pod designed for pediatric users. The dual-hormone trial entered a pivotal Phase III stage in December, with topline data expected in the third quarter. Additionally, the company secured breakthrough device designation from U.S. regulators for its slim-profile Pod, facilitating an expedited review process. Insulet’s R&D spending reached $128 million in the latest fiscal year, representing 9% of total revenue and up from 7% the previous year, underscoring its commitment to innovation in automated insulin delivery.

Analyst consensus reflects strong conviction in Insulet’s growth trajectory, with 21 buy ratings and two hold ratings recorded by leading research firms. The average price target implies a potential upside of more than 30% relative to current levels, driven by optimism around international expansion and product pipeline catalysts. Institutional ownership stands at roughly 80% of outstanding shares, led by healthcare-focused funds and long-term pension investors. During the past quarter, insiders and major shareholders added approximately 150,000 shares collectively, signaling confidence in the company’s strategic direction and near-term milestones.